marstacimab

ASH: Pfizer, swimming in crowded waters, eyes wide impact for sickle cell, hemophilia assets
Fierce Biotech
Sun, 12/10/23 - 11:12 pm
Pfizer
sickle cell disease
ASH
marstacimab
Pfizer's hemophilia drug hits in phase 3, giving it a chance to leapfrog Novo Nordisk
Fierce Biotech
Tue, 05/30/23 - 10:07 am
Pfizer
Novo Nordisk
clinical trials
hemophilia
marstacimab
Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy
Pharmaceutical Business Review
Tue, 11/24/20 - 10:23 am
Pfizer
clinical trials
marstacimab
hemophilia
anti-TFPI